United States of America v. Avanir Pharmaceuticals, Inc.

CourtDistrict Court, N.D. Ohio
DecidedJuly 28, 2020
Docket5:15-cv-00611
StatusUnknown

This text of United States of America v. Avanir Pharmaceuticals, Inc. (United States of America v. Avanir Pharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States of America v. Avanir Pharmaceuticals, Inc., (N.D. Ohio 2020).

Opinion

UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION

UNITED STATES OF AMERICA, ex rel. ) CASE NO. 5:15-cv-0611 KEVIN MANIERI, ) ) ) Plaintiff-Relator, ) JUDGE SARA LIOI ) vs. ) MEMORANDUM OPINION ) AND ORDER AVANIR PHARMACEUTICALS, INC., ) ) ) Defendant. )

Before the Court is the motion of plaintiff Kevin Manieri (“Manieri” or “plaintiff”) for leave to file a second amended complaint. (Doc. No. 46 [“Mot.”].) Defendant Avanir Pharmaceuticals, Inc. (“Avanir” or “defendant”) filed its opposition (Doc. No. 48 [“Opp’n”]) and Manieri filed a reply (Doc. No. 49 [“Reply”].) For the reasons and in the manner set forth herein, plaintiff’s motion is granted. I. BACKGROUND1 On March 27, 2015, Manieri filed a complaint, individually and on behalf of the United States of America, alleging that defendant Avanir had violated the False Claims Act, 31 U.S.C. § 3729, et seq. (“FCA”), and the Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b) (“AKS”). (Doc. No. 1, Complaint, [“Compl.”] ¶ 1.) Manieri alleged that Avanir pays speaking fees to physicians around the country in exchange for their promise to prescribe a drug that Avanir sells as a treatment for a rare neurological condition. He alleged that this conduct led to the submission of false or

1 All page number references herein are to the page identification number generated by the Court’s electronic docketing system. fraudulent claims for prescriptions to Medicare patients written in 2013 and 2014. (Id. ¶¶ 2; 136– 53.) Manieri also alleged that he had been employed by Avanir from August to November 2014. (Id. ¶ 10.) He claimed his employment was terminated in retaliation for his objections to the illegal

kickback scheme in conversations with Avanir’s Vice President of Sales, Michael McFadden (“McFadden”). (Id. ¶¶ 154–61.) Manieri’s claims against Avanir relating to the submission of false claims, brought on behalf of the United States of America (which had intervened on September 26, 2019 (see Doc. No. 25), after first seeking nine (9) extensions of time to intervene), were resolved on October 24, 2019 by way of a settlement and joint stipulation of partial dismissal. (See Doc. No. 28.) On December 17, 2019, Manieri filed his first amended complaint (Doc. No. 35, First Amended Complaint [“FAC”]),2 wherein he again alleged that Avanir terminated his employment in retaliation for his objection to certain physicians’ “participation in the speaker program as a means to unlawfully induce prescriptions of [the drug].” (Id. ¶ 6.) Despite that allegation in the

introduction to the FAC, when Manieri described in detail the circumstances surrounding the termination of his employment, he alleged (exactly as he had in his initial complaint) that, during a meeting in Boston on November 17, 2014, another regional business manager (“RBM”) complained to Manieri that some of the RBM’s direct reports were not performing well. Manieri suggested that the RBM consider terminating the underperforming employees. (Id. ¶¶ 147–48; Compl. ¶¶ 131–32.) Another sales representative overheard Manieri’s comment and disagreed;

2 Manieri did not seek leave to file the first amended complaint. Fed. R. Civ. P. 15 (a)(1)(A) provides that a party may amend its pleading once as a matter of course within 21 days after serving it. Although there is nothing in this record to suggest when Avanir was served, it has never challenged the FAC’s timeliness nor argued that Manieri should have sought leave to amend. 2 that representative subsequently passed on a complaint to Manieri’s superior, VP of Sales McFadden. (FAC ¶ 149; Compl. ¶ 132.) A few days later, on November 21, 2014, during a phone call, McFadden reprimanded Manieri for his comment to the RBM and criticized his management skills—something McFadden had never done before. (FAC ¶ 150; Compl. ¶ 133.) Manieri further

alleged that McFadden told him he had “‘enough here to terminate you, but I’ll give you an opportunity to resign.’” (FAC ¶ 151; Compl. ¶ 134.) “Mr. McFadden did not cite any reasons for the termination other than the suggestion [p]laintiff Manieri made to his direct report at the November 17 meeting.” (Id.) Manieri then alleged: “As the result of this conversation, Avanir terminated [p]laintiff Manieri’s employment on November 21, 2014.” (FAC ¶ 152 (emphasis added).) Notably, for purposes of the instant request to amend a second time, the phrase in italics was not included in the initial complaint, but was added to the FAC filed on December 17, 2019. (See Compl. ¶ 135.) Manieri then alleged, in count one, that McFadden’s criticism of his management practices during the November 21, 2014 conversation was “pretext for retaliation for [his] opposition to

Avanir’s illegal kickback scheme[,]” and that “Avanir terminated [his] employment in retaliation for his opposition to Avanir’s kickback scheme, in violation of 31 U.S.C. § 3730(h).” (FAC ¶¶ 165–66.) The corresponding allegations were in count four of the initial complaint. (See Compl. ¶¶ 158–59.) Avanir filed a motion to dismiss the FAC, arguing that Manieri failed to sufficiently allege a claim for retaliation, having provided only “isolated and innocuous statements [that] do not come anywhere close to showing that [p]laintiff engaged in conduct protected by the FCA.” (Doc. No. 45, Motion to Dismiss [“MTD”], at 224 (citing FAC ¶¶ 93, 99).) Avanir also argued that Manieri failed to allege that Avanir knew that he had engaged in protected conduct and, further, that 3 plaintiff’s own complaint concedes the existence of a legitimate basis for his termination. (Id. at 225.) On the day his response to the motion to dismiss was due, Manieri filed the instant motion for leave to file a second amended complaint to set forth more (and, as it turns out, different and

sometimes inconsistent) factual detail around his alleged protected conduct and termination. He also sought (and was granted) an unopposed stay of the briefing on Avanir’s motion to dismiss pending resolution of the motion for leave to file a second amended complaint. (See Doc. No. 47; Non-Document Order (3/19/2020).) II. DISCUSSION A. Legal Standard Fed. R. Civ. P. 15(a)(2) provides that “[t]he court should freely give leave [to amend] when justice so requires.” “Guided by that overarching principle, the district court may weigh the following factors when considering a motion to amend: undue delay or bad faith in filing the motion, repeated failures to cure previously-identified deficiencies, futility of the proposed

amendment, and lack of notice or undue prejudice to the opposing party.” Knight Cap. Partners Corp. v. Henkel AG & Co., KGaA, 930 F.3d 775, 786 (6th Cir. 2019) (citation omitted). B. Rule 15 Analysis Manieri does not explain why “justice . . . requires” that he be permitted to amend his complaint a second time in the manner that he suggests. He simply quotes the rule and asserts that “the thrust of [the Rule] is to reinforce the principle that cases ‘should be tried on their merits rather than the technicalities of pleadings.’” (Mot. at 240 ¶ 4, quoting Moore v. City of Paducah, 790 F.2d 557, 559 (6th Cir.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
United States of America v. Avanir Pharmaceuticals, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-of-america-v-avanir-pharmaceuticals-inc-ohnd-2020.